Actively Recruiting
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
Led by Ottawa Heart Institute Research Corporation · Updated on 2026-05-01
346
Participants Needed
3
Research Sites
247 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e. inotropes) among critically ill patients admitted to the Cardiac Intensive Care Unit (CICU). To do this, the investigators will conduct a multi-centre, double blind, randomized control trial with patients who are deemed to require these medications by their treating physician to one of the two most commonly used agents in Canada (Milrinone or Dobutamine) or placebo. Each patient will be closely monitored by their healthcare team. The dose of medication will be adjusted according to each patients' clinical status. After 12 hours, the participants will move to open label treatment and any continued use of inotropes will be at the discretion of their treating physician.
CONDITIONS
Official Title
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients 18 years of age or older admitted to an intensive care unit
- Diagnosis of cardiogenic shock classified as SCAI class C or D
You will not qualify if you...
- Unable or unwilling to provide informed consent by participant or substitute decision maker
- Currently pregnant or breastfeeding
- Presenting with out-of-hospital cardiac arrest (OHCA)
- Received milrinone or dobutamine within 24 hours before planned randomization
- Severe obstructive valvular heart conditions such as aortic stenosis or mitral stenosis
- Presence of dynamic left ventricular outflow tract obstruction
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
Not Yet Recruiting
2
Hamilton Health Sciences
Hamilton, Ontario, Canada, L8L 2X2
Actively Recruiting
3
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y4W7
Actively Recruiting
Research Team
R
Rebecca Mathew, MD
CONTACT
B
Baylie Morgan, RN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here